Research Report : Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in Middle Income Countries

Research Report : Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in Middle Income Countries
Independent study conducted by Charles River Associates (CRA) commissionedinIFPMA.
January 2014,

The study demonstrates “that there is clear evidence that innovative medicines have delivered significant value by reducing healthcare costs and benefitting both patients and wider society. However, there remains enormous untapped potential of adopting innovative medicines more widely in middle-income countries (MICs). This can be achieved by national prioritization, investments in healthcare infrastructure and building better epidemiological and cost databases for effective evaluation of therapies.” The study examined the value of innovation in five key therapy areas: coronary heart disease (CHD), depression, diabetes, HIV/AIDS, and rotavirus infection.

In the case of rotavirus, the most common cause of severe diarrhoea among children in both industrialized and developing countries, Tim Wilsdon, CRA Vice President, said, “We compared the value that two recently-launched vaccines yielded in Brazil and Australia. The major benefit seen in both countries was a direct drop in hospitalization costs, but in Brazil we also witnessed a major decline in related mortality rates. So obviously both benefitted from these innovations, but given the nature of the disease burden the added value was greater for Brazil.”

Commenting on the study findings, Eduardo Pisani, IFPMA Director General, added that “We now have evidence that in MICs innovative therapies have the potential to create significant value that goes far beyond pricing and reimbursement. Both the social and economic benefits should be taken into account in any calculation of value.”…

[Full report] and [CRA key findings]
http://www.ifpma.org/news/news-releases/news-details/article/new-study-captures-the-value-of-new-medicines-in-m.html